Ajanta Pharma launches Levetiracetam Immediate-Release Tablets

Ajanta Pharma has launched Levetiracetam Immediate-Release Tablets (250mg, 500mg, 750mg, 1000mg) in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Levetiracetam cures epileptic neurological disorder like numbness, blindness, paralysis or fits and is a bioequivalent generic version of Keppra.

The company’s launch of Levetiracetam Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (FDA) has granted Ajanta Pharma's eight ANDAs final approvals and two tentative approvals. An additional 16 ANDAs are pending approval from the FDA.

Ajanta Pharma is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries.